Abstract
Paradigm shifts in patient care all too frequently result in recommendations for more costly medications, procedures, or devices. Clinicians rarely encounter newer therapies that improve outcomes at a lower cost—such as the “rediscovery” of metformin therapy for type 2 diabetes.1 The article by McKinnell et al2 in this issue of Mayo Clinic Proceedings, coupled with 2011 practice guidelines from the Infectious Diseases Society of America (IDSA) and European Society for Microbiology and Infectious Diseases,3 provides important and welcome changes in recommendations for cost-effective management of uncomplicated lower urinary tract infection (UTI) in women.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
